Nutritional supplements and methods of supplementation affecting the endocannabinoid system

Abstract

Nutritional supplements and methods of nutritional supplementation affecting the endocannabinoid system are provided. These nutritional supplements and methods of nutritional supplementation support the endocannabinoid systems of subjects by providing a blend of hemp oil, black pepper oil, black cumin seed oil, and white frankincense oil to prime ECS receptors and activate them to provide improvements to the ECS in a subject, affecting their pain response, mood, stress response, and sleep.

Claims

1. A method of administering a nutritional supplement to a subject, comprising: identifying that the subject is in need of improvement of mood; and administering the nutritional supplement to the subject, wherein the nutritional supplement is a composition that comprises: between about 15 mg to about 50 mg full spectrum hemp oil; between about 5 mg and about 50 mg black pepper oil, which comprises b-caryophyllene; between about 1 mg and about 20 mg black cumin seed oil, which comprises thymoquinone; between about .5 mg and about 5 mg white frankincense oil; and between about 800 mg and about 900 mg olive oil.

Description

DETAILED DESCRIPTION

(1) As used herein, treatment means any manner in which the symptoms or pathology of a condition, disorder or disease are ameliorated or otherwise beneficially altered. Treatment also encompasses any pharmaceutical use of the compositions herein.

(2) The supplement compositions of the present disclosure may be administered in a variety of suitable dosage forms, including, without limitation, tablets, capsules, granules, powders, liquids, liposome inclusions, ointments, gels, external powders, sprays, inhalable powders, injectable preparations (solutions, suspensions, emulsions, solids to be dissolved when used, etc.), eye drops, eye ointments, suppositories, and the like can be selected appropriately depending on the administration method, and the compositions of the present disclosure can be accordingly formulated. Formulation in general is described in references including Comprehensive Medicinal Chemistry, Volume 5, Editor Hansch et al, Pergamon Press 1990.

(3) As used herein, any range set forth is inclusive of the end points of the range unless otherwise stated.

(4) As used herein, “effective amount” refers to an amount of a substance which is sufficient to achieve its intended purpose or effect. Various biological factors may affect the ability of a delivered substance to perform its intended task. Therefore, an “effective amount” may be dependent on such biological factors. An effective amount of a compound for treating a disorder is an amount that is sufficient to ameliorate, or in some manner reduce a symptom or stop or reverse progression of a condition. Such amount may be administered as a single dosage or may be administered according to a regimen whereby it is effective. The achievement of therapeutic effects may be measured by a physician or other qualified medical personnel using evaluations known in the art, (for example with testosterone supplementation therapy, physical examination, blood and saliva tests may be used), it is recognized that individual variation and response to treatments may make the achievement of therapeutic effects a subjective decision.

(5) Further, determination of the effectiveness of the amount is well within the knowledge and ability of one of ordinary skill in the art.

(6) As used herein, “administration,” and “administering” may be used interchangeably, and refer to the act of presenting, applying, or introducing a drug to a subject in order to achieve a desired physiological or psychological response.

(7) As used herein, amelioration of the symptoms of a particular disorder by administration of a particular pharmaceutical composition refers to any lessening, whether permanent or temporary, lasting or transient that can be attributed to or associated with administration of the composition.

(8) Many individuals struggle with pain, low moods, poor management or strong responses to stress and low-quality sleep. The present disclosure provides nutritional supplements and methods of nutritional supplementation to support the ECS of an individual, and thus to support improvements in pain, mood, stress and sleep.

(9) Without being limited to any one theory, it is understood that the supplements and methods of supplementation disclosed herein act using a previously-unknown mechanism of first priming the ECS receptors, and then activating them, providing benefits superior to currently available solutions.

(10) In some embodiments, the use of full-spectrum hemp oil provides a range of 100+ naturally-occurring phytocannabinoids, instead of delivering a single cannabinoid, as is done in many other available supplements. This may result in synergistic effects not elicited by administration of a single cannabinoid compound such as CBD. It is further believed that phytocannabinoids preferentially bind to the CB1 receptor, especially those found in the brain areas of the ECS, affecting reactions to stress, anxiety, mood, pain and sleep.

(11) The supplements and methods of supplementation described in the present disclosure further provide black pepper oil comprising terpenes which bind preferentially to the CB2 receptors of the ECS, synergistically easing pain and inflammation in a subject receiving the compositions of this disclosure.

(12) Lastly, the nutritional supplements and methods of nutritional supplementation disclosed further provide polyphenols from white frankincense oil and quinones from black cumin seed oil. Without being limited to any one theory, these polyphenols and quinones act together and/or separately to prime the full range of CB1 and CB2 receptors to prepare them to receive and bind the hemp phytocannabinoids provided by the supplements of this disclosure.

(13) By priming the ECS while administering a full-spectrum hemp oil as a source of phytocannabinoids, the nutritional supplements and methods of supplementation of the present disclosure provide a superior and unexpectedly complete priming and activation of the ECS, resulting in superior effects on the stress response, pain, mood/anxiety and sleep of a subject.

(14) It should be noted that the methods described herein describe possible implementations, and that the operations and the steps may be rearranged or otherwise modified and that other implementations are possible. Further, aspects from two or more of the methods may be combined.

(15) As used herein, including in the claims, “or” as used in a list of items (e.g., a list of items prefaced by a phrase such as “at least one of” or “one or more of”) indicates an inclusive list such that, for example, a list of at least one of A, B, or C means A or B or C or AB or AC or BC or ABC (i.e., A and B and C). Also, as used herein, the phrase “based on” shall not be construed as a reference to a closed set of conditions. For example, an exemplary step that is described as “based on condition A” may be based on both a condition A and a condition B without departing from the scope of the present disclosure. In other words, as used herein, the phrase “based on” shall be construed in the same manner as the phrase “based at least in part on.”

(16) In the appended figures, similar components or features may have the same reference label. Further, various components of the same type may be distinguished by following the reference label by a dash and a second label that distinguishes among the similar components. If just the first reference label is used in the specification, the description is applicable to any one of the similar components having the same first reference label irrespective of the second reference label, or other subsequent reference label.

(17) The description set forth herein, in connection with the appended drawings, describes example configurations and does not represent all the examples that may be implemented or that are within the scope of the claims. The term “exemplary” used herein means “serving as an example, instance, or illustration,” and not “preferred” or “advantageous over other examples.” The detailed description includes specific details for the purpose of providing an understanding of the described techniques. These techniques, however, may be practiced without these specific details. In some instances, well-known structures and devices are shown in block diagram form in order to avoid obscuring the concepts of the described examples.

(18) The description herein is provided to enable a person skilled in the art to make or use the disclosure. Various modifications to the disclosure will be readily apparent to those skilled in the art, and the generic principles defined herein may be applied to other variations without departing from the scope of the disclosure. Thus, the disclosure is not limited to the examples and designs described herein, but is to be accorded the broadest scope consistent with the principles and novel features disclosed herein.